Investee Company Update: Little Green Pharma Ltd

SEED Innovations Ltd, the AIM-listed investment firm providing access to high-growth, disruptive life sciences and technology ventures typically out of reach for everyday investors, is pleased to note that its portfolio company, Little Green Pharma Ltd ('LGP'), has published its quarterly activities report and Appendix 4C for the period ending 31 December 2024 on the ASX.

The Company owns 7,324,796 ordinary shares in LGP representing ca. 2.4% of LGP's issued share capital.

Commenting on the announcement, Ed McDermott, CEO of Seed said: "LGP continues to demonstrate impressive year-over-year growth, with quarterly revenue rising 75% to A$9.5 million and record December revenue of A$3.6 million. The company's strong cash position and minimal long-term debt reinforce its solid financial position, while its net tangible assets remain significantly above enterprise value. Notably, expansion in Germany and the UK is gaining momentum, with A$1.0 million in German flower sales in December and A$6.0 million in binding purchase orders for these markets over the coming quarters. These results further validate LGP's strategy, and we remain confident in its ability to sustain this momentum."

Quarterly Activities Report and Appendix 4C

Highlights

• Revenue of $9.5 million (unaudited), up 75% on prior corresponding period with record $3.6 million in December
• Cash receipts of $10.0 million, up 90% on prior corresponding period
• FY25Q3 year to date revenue of $27.0 million (unaudited) already surpassing prior full year revenue of $25.6 million
• Strong German and UK market growth with $1.0 million in German flower sales in December and $6.0 million in binding purchase orders for Germany and UK over coming two quarters
• Additional 2tpa grow room opened in Denmark to meet increased demand
• Launch of new Lush Labs craft flower brand, three new oil products and one vaporiser product
• Reset trial treatment phase completed to positive patient feedback
• Health House due diligence acquisition completed and Company negotiating SPA
• Cash in bank of $3.7 million

The announcement in full can be accessed from the following link: Quarterly-Activities-Report-and-Appendix-4C.pdf

Little Green Pharma